CELENTYX LIMITED
ActiveKey figures
CELENTYX LIMITED does not disclose its turnover in its latest accounts; the profit for the year is as stated in the accounts.
Ratios
2025Sector comparison
SIC 72110Where the company stands among the 3,991 active companies whose first SIC code is 72110 (Research and experimental development on biotechnology).
- BRACCO HORIZONS LIMITED£526.1m
- TAURX THERAPEUTICS MANAGEMENT LTD.£470.3m
- LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED£317m
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED£289.2m
- GENOME RESEARCH LIMITED£273.7m
- MODERNA BIOTECH UK LIMITED£236.5m
- CURIA (SCOTLAND) LIMITED£183m
- ASTEX THERAPEUTICS LIMITED£163.6m
- HORIZON DISCOVERY GROUP LIMITED£159.6m
- AMGEN LIMITED£134.4m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 3,991. The line on each bar marks the median.
Summary: CELENTYX LIMITED
What kind of company is it?
CELENTYX LIMITED is a private limited company registered with Companies House under company number 05304904. It was incorporated on 6 Dec 2004. Its status is active. The registered office is in Birmingham (B15). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Profit for the year was £129,032. Net assets were £1,108,121, up 13.5% on the previous year. Cash at bank and in hand was £727,511. Total assets were £1,137,557 and total liabilities £90,563. The company had an average of 0 employees. Figures are available for 6 financial years (2020–2025).
How does it compare with similar companies?
Compared with 3,991 active companies whose first SIC code is 72110: By net assets it ranks higher than 82% of them (median £20,587). By total assets it ranks higher than 75% of them (median £124,497). By cash it ranks higher than 74% of them (median £101,426). By number of employees it ranks lower than 65% of them (median 1). It is older than 94% of them (median age 5.4 years).
Has it received government grants?
It is recorded as the recipient of 2 central government grants worth £165.5k, from Department for Business, Energy and Industrial Strategy.
What do public registers and reports show?
HMRC lists it as an importer of goods, mainly miscellaneous chemicals, pharmaceuticals, plastics.
Who runs and controls the company?
The company has 2 current directors. One person with significant control is registered.
When are its next filings due?
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 30 Dec 2026.
Control structure
Professor Nicholas Mark Barnes is the only person with significant control on record for this company; the PSC register shows no further links.
Filed accounts2020–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Profit for the year | 111,733 | — | 199,940 | 206,327 | 129,032 |
| Cash at bank and in hand | 410,745 | 542,677 | 743,981 | 574,746 | 727,511 |
| Total assets | 777,895 | 822,472 | 1,154,678 | 1,183,862 | 1,137,557 |
| Total liabilities | 161,124 | 342,510 | 454,414 | 266,408 | 90,563 |
| Net assets / total equity | 639,488 | 565,778 | 768,066 | 976,741 | 1,108,121 |
| Average number of employees | 9 | 12 | 12 | 0 | 0 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Government grants
2 grantsCELENTYX LIMITED is recorded as the recipient of 2 central government grants since 2021, together worth £165.5k.
- Development of a SARS-CoV-2 spike protein binding assay using human epithelial cells for COVID-19 therapy discovery and developmentDepartment for Business, Energy and Industrial Strategy · £6,360 · UKRI - Innovate UK - Scheme 22/23
- Development of a SARS-CoV-2 spike protein binding assay using human epithelial cells for COVID-19 therapy discovery and developmentDepartment for Business, Energy and Industrial Strategy · £159,106 · ALB - UKRI - Innovate UK grant awards in 20-21
From the Government Grants Register published by the Cabinet Office (financial years 2016/17 onwards, Open Government Licence v3.0). It covers grants from central government departments and their agencies where the register states the recipient's company number and the recipient name matches this company; grants from local authorities, lottery distributors and devolved governments are not included.
Registers and licences
Listed by HMRC as an importer of goods in 4 of the last 12 months on record, most recently August 2026. Main goods: miscellaneous chemicals, pharmaceuticals and plastics.
From HMRC's monthly lists of importers and exporters. Traders can ask to be left off the lists, so absence does not mean a company does not trade.
Sources: Charity Commission for England and Wales, Care Quality Commission, Home Office and HM Revenue & Customs, under the Open Government Licence v3.0. Entries marked ‡ come from lists that do not state a company number and were linked by an exact match on the registered name.
History
34 events- Financial year 2025 endedAccounts: net assets £1.1m, 0 employees
- John GORDON resignedDirector
- Professor John Gordon ceased to be a person with significant control
- Financial year 2024 endedAccounts: net assets £976.7k, 0 employees
- Financial year 2023 endedAccounts: net assets £768.1k, 12 employees
- Financial year 2022 endedAccounts: net assets £565.8k, 12 employees
- Professor Nicholas Mark Barnes registered as a person with significant control
- Professor John Gordon registered as a person with significant control
Earlier events (26)
- Financial year 2021 endedAccounts: net assets £639.5k, 9 employees
- Financial year 2020 endedAccounts: net assets £525.4k, 9 employees
- Rachael HART resignedSecretary
- Jonathan Mercer WATKINS resignedDirector
- Anna Gail HAYES resignedDirector
- MERCIA FUND MANAGEMENT (NOMINEES) LIMITED resignedDirector (corporate)
- Rachael HART appointedSecretary
- Nadim KHAN resignedSecretary
- Mark Andrew PAYTON resignedDirector
- MERCIA FUND MANAGEMENT (NOMINEES) LIMITED appointedDirector (corporate)
- Anna Gail HAYES appointedDirector
- Nadim KHAN appointedSecretary
- Peter Robin CUNLIFFE resignedSecretary
- Mark Andrew PAYTON appointedDirector
- John GORDON resignedSecretary
- Peter Robin CUNLIFFE appointedSecretary
- Alan Keith BOYD appointedDirector
- Brian Richard TURNER resignedSecretary
- James Douglas Strachan GORDON resignedDirector
- Nicholas Mark BARNES appointedDirector
- John GORDON appointedSecretary
- John GORDON appointedDirector
- Jonathan Mercer WATKINS appointedDirector
- Brian Richard TURNER appointedSecretary
- James Douglas Strachan GORDON appointedDirector
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.